Hanly and coworkers have reported the results of a large lupus cohort study involving 1827 patients. SLE patients were enrolled early in their disease (0.5 years) and were followed for a mean of 4.6 years.
Lupus nephritis (LN) was found in 38% patients, with 81% presenting with LN at enrolment and 19% during follow-up. LN was more likely in patients who were younger, male and ethnic (African, Asian or Hispanic).
Wayne J Riley, MD, MPH, MBA, MACP, president of the American College of Physicians (ACP) sent a letter to the Centers for Disease Control and Prevention (CDC) reacting to its Draft Guideline for the Use of Opioids for Chronic Pain.
Drug prices increased an average of 10% in 2015 (after a 13.5% increase in 2014) and includes big name drugs from major pharmaceutical companies. This comes at a time when generic drugs have skyrocketed to the point of inciting a Senate investigation, and rare drugs for rare disorders being overpriced by companies like Valeant.
As the never-ending battle with refractory gout continues, the need for more safe and effective treatments remains. Often, steady remission and target urate levels are not achieved with allopurinol alone.
A patient recently asked me, “What do you think it’s like to have RA” and “How would you describe it to someone you just met?” Could I walk a mile in her shoes? Here's my version and theirs.
Three European registries analyzed their cohorts for outcomes that may be related to seropositivity for anticitrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anticarbamylated protein (anti-CarP) antibodies.
If you are responsible for the outcome and welfare of patients – you need prescribing rules.
If you are supervising others or responsible for the training of those learning rheumatology – you need prescribing rules.
Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plus TCZ), including the ACT-RAY, ACT-SURE and FUNCTION clinical trials.
A new Cochrane Review published today shows that targeting exercises to muscles that support and control the spine offers another strategy to reduce pain and disability caused by lower back pain.
Lower back pain is one of the most common health conditions worldwide. It can have substantial health and economic costs as people experience disability and general ill health, leading them to need time off work.
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPage Today.
SpA is a common disease, but with large variation in reported prevalence estimates, partly explained by differences in demographical and methodological characteristics.
Was 2015 a good year for psoriasis, IL-17, biosimilars, narcotics, the ACR and gout? Our year end review discusses the most impactful news and research from the last 12 months.
An administrative claims study of lupus patients drawn from the United States National Inpatient Sample between 2000 to 2011, studied hospitalization rates related to bacteremia, pneumonia, opportunistic fungal infection, herpes zoster, cytomegalovirus, or pneumocystis pneumonia (PCP).
A prospective study was conducted in Germany to establish predictors of 1 year survival after a hip fracture in elderly people.
The need for such study arose from the fact that patient outcomes remain disappointing within the first year after the fracture, regardless of advanced surgical care.
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis. (Citation source http://buff.ly/1VAndEl)
